Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease

Meng-Tzu Weng; I-Lun Shih; Chien-Chih Tung; Yew-Loong Leong; Ming-Jium Shieh; Cheng-Yi Wang; Jau-Min Wong; Yen-Hsuan Ni; Shu-Chen Wei

doi:10.5217/ir.2021.00042

Articles

Page Path: HOME > Intest Res > Volume 20(2); 2022 > Article

Original Article Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease: Meng-Tzu Weng¹, I-Lun Shih², Chien-Chih Tung³, Yew-Loong Leong^1,4, Ming-Jium Shieh⁵, Cheng-Yi Wang¹, Jau-Min Wong¹, Yen-Hsuan Ni⁶, Shu-Chen Wei^1,; Intestinal Research 2022;20(2):224-230.
DOI: https://doi.org/10.5217/ir.2021.00042
Published online: February 8, 2022

¹Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan

²Department of Medical Imaging, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan

³Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan

⁴Good Liver Clinic, Taipei City, Taiwan

⁵Department of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan

⁶Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan

Correspondence to Shu-Chen Wei, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei City 100, Taiwan. Tel: +886-2-23123456 (ext. 65768), Fax: +886-2-23947927, E-mail: shuchenwei@ntu.edu.tw

• Received: March 12, 2021 • Revised: April 2, 2021 • Accepted: April 10, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

4,523 Views
266 Download
8 Web of Science
7 Crossref
8 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

See letter "Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?" in Volume 20 on page 157.

Abstract

Background/Aims
Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD). We aimed to evaluate the prevalence, clinical manifestation, and outcomes of PSC in Taiwanese patients with IBD.
Methods
This retrospective study enrolled patients with IBD admitted from January 1, 1996, to December 31, 2018, to National Taiwan University Hospital. A case-matched analysis was performed comparing patients with IBD with and without PSC according to age, sex, and time of admission, with ratios of 1:4 and 1:2 in the adult and pediatric groups, respectively.
Results
In total, 763 patients with IBD were enrolled, 12 of whom were also diagnosed with PSC (1.57%). All these patients had ulcerative colitis (UC). A greater incidence of IBD with PSC was observed in younger patients than in older patients. Male sex was a risk factor for PSC in pediatric patients with IBD (P=0.015); 75% of these patients were diagnosed with PSC along with or after the diagnosis of UC. There was no significant difference in colitis extent and severity between the groups; however, a higher proportion of rectal sparing was observed in patients with PSC (P=0.001). There was no significant difference in cancer development between the groups (P=0.679).
Conclusions
A 1.57% prevalence of PSC was observed in Taiwanese patients with IBD. The majority of patients with IBD and PSC were men and were diagnosed at a younger age. Hence, routine evaluation of biliary enzymes and liver imaging is recommended in young male patients with IBD.
Keywords: Primary sclerosing cholangitis; Inflammatory bowel disease; Ulcerative colitis

INTRODUCTION

Primary sclerosing cholangitis (PSC) is a chronic disease that affects the biliary tract. Progressive inflammation and fibrosis cause intrahepatic and extrahepatic bile duct obstruction and dilatation. The diagnosis of PSC is based on cholestatic biochemical profile and cholangiography. The annual incidence of PSC was 0.5–1.3 per 100,000 individuals in Western countries [1,2], whereas no relative information is available in Asian countries. The prevalence of PSC was approximately 0.095–0.13 per 10,000 inhabitants in Asian countries, which is 10-fold lower than the prevalence in Western countries [3].

Although the exact etiology and pathogenesis of PSC are still unknown, several studies have shown an association of PSC with certain genetic, environmental, and immunologic factors. There is no curative treatment for PSC, and a considerable number of patients develop severe clinical sequelae, such as portal hypertension, liver cirrhosis, and end-stage liver disease, eventually requiring liver transplantation (LT). Moreover, patients with PSC have a higher lifetime risk of cholangiocarcinoma and gall bladder cancer.

PSC is strongly associated with inflammatory bowel disease (IBD), especially ulcerative colitis (UC). Approximately 47%–76% and 20%–37% of patients with PSC had IBD in Western and Asian countries, respectively [1]. The proportion of UC was over 75% in these cases [4]. By contrast, PSC was less commonly diagnosed in patients with IBD, occurring in approximately 2.4%–7.5% of patients with UC and approximately 3% of patients with Crohn’s disease (CD) in Western countries [4]. With regard to Asian countries, PSC was identified in 0.3% and 0.2% of Korean patients with UC and CD, respectively [5]. Approximately 25% of patients with IBD and PSC developed PSC before the diagnosis of IBD [6].

Patients with IBD and concomitant PSC were characterized by pancolitis, backwash ileitis, rectal sparing, and increased risk of colorectal cancer (CRC) and cholangiocarcinoma [7-9] in Western countries, whereas the relationship between PSC and IBD was less frequently reported in Asian countries. Previously, both IBD [10] and PSC [5,11] were less prevalent in Taiwan as well as in overall Asia. Therefore, limited data were available regarding PSC and IBD among Asians. With the increasing prevalence of IBD in Taiwan in recent decades [10], we sought to evaluate possible factors associated with PSC that can aid earlier diagnosis of PSC in IBD. Compared with patients with IBD and without PSC, those with concomitant IBD and PSC have a higher risk of hepatic failure. Earlier identification and preparation for LT might be helpful for improving outcomes in such patients.

METHODS

1. Patients

This retrospective study was conducted to review patients with IBD admitted to National Taiwan University Hospital from January 1, 1996, to December 31, 2018. This study was approved by the Institutional Review Board of National Taiwan University Hospital (IRB No. 201912236RINC). This study is a retrospective study using anonymous clinical data review and so informed consent was waived. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used for the detection of UC (ICD-9-CM code 556.9) and CD (ICD-9-CM code 555.9). The type of IBD and the extent and severity of colitis were recorded. The diagnosis of IBD was based on a combination of clinical, endoscopic, and histologic features and the exclusion of an infectious etiology. The extent of colitis was classified as proctitis (E1), left sided (E2), and extensive (E3) in UC [12] according to the Montreal classification. The severity of disease (mild, moderate, or severe) was determined according to Truelove and Witts criteria [8]. Patients with IBD with concomitant PSC were identified from the radiology information system of National Taiwan University Hospital. All types of radiological reports with the keyword “sclerosing” and “cholangitis” were searched, and the charts of patients who repeatedly underwent computed tomography, magnetic resonance imaging, or percutaneous biliary procedures were reviewed. The diagnostic criteria of PSC were based on cholestatic biochemical profile and cholangiography. Studies involving patients with IgG4-associated cholangitis and secondary causes of sclerosing cholangitis were excluded. Clinical information, including demographic data, laboratory and pathologic reports, treatment regimens, the area involved in PSC, the disease course, and a history of cancer or LT, was assessed. A total of 12 patients with concomitant IBD and PSC were identified. Adult patients with IBD and PSC were matched with those with IBD but without PSC, as a comparison group, with a 1:4 ratio, according to sex, age, and time of hospital admission. Because the number of patients in the pediatric group (patients aged below 18 years) was small, pediatric patients with IBD and PSC were matched with those with IBD but without PSC in a 1:2 ratio. Differences in clinical information and outcomes between patients with IBD and PSC and those with IBD but without PSC were compared.

2. Statistical Analysis

Continuous variables are expressed as the mean ± standard deviation. Categorical variables are expressed as the frequency (percentage). Student t-test was used to compare quantitative variables, and the chi-square statistic or Fisher exact test was used to compare categorical variables between the 2 cohorts. A P-value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 11.0 program (SPSS Inc., Chicago, IL, USA).

RESULTS

1. Demographic Characteristics of Patients with UC

A total of 763 patients were diagnosed with IBD (380 with CD and 383 with UC); 12 of them with UC had concomitant PSC. The incidence of PSC was 1.57% in patients with IBD and 3.1% in patients with UC. Patients with UC and PSC were significantly younger than those with UC but without PSC (median age: 22.5 and 49.0 years, respectively; P=0.001). Male predominance was noted in both the groups (83.3% and 58.5%, respectively; P=0.085). After the subgroup analysis of pediatric patients with UC, a significantly higher proportion of male patients was observed in the PSC group than in the non-PSC group (100% and 38.2%, respectively; P=0.015). The demographics of patients with IBD with and without PSC are summarized in Table 1. The basic characteristics of 12 patients with UC and PSC are listed in Table 2. The majority (75%) of these patients were diagnosed with PSC along with or after the diagnosis of UC. The typical PSC magnetic resonance imaging images were shown in Supplementary Fig. 1.

2. Comparison of Clinical Characteristics between Patients with UC with and without PSC

Among the 12 patients who had concomitant UC and PSC, 7 were adults. They were matched with patients with UC but without PSC according to sex, age, and the year of admission as a control group, at a 1:4 ratio in the adult group and 1:2 ratio in the pediatric group. Finally, a total of 38 matched patients (28 adults and 10 children) with UC were included as controls. The clinical characteristics of these patients are listed in Table 3. Underlying diseases, namely hypertension (8.3% vs. 5.3%, P=0.696), diabetes mellitus (0% vs. 5.3%, P=0.417), hyperlipidemia (0% vs. 2.6%, P=0.570), coronary artery disease (0% vs. 5.3%, P=0.417), chronic kidney disease (8.3% vs. 5.3%, P=0.696), and chronic viral hepatitis, were comparable between the groups (all P>0.05). Moreover, there was no statistical difference in the colitis-involved area and disease severity between the groups, whereas patients with UC and PSC had higher proportion of rectal sparing, compared with patients with UC but without PSC (25% and 0%, respectively; P=0.001). The frequency of backwash ileitis did not differ between the 2 groups (33.3% vs. 9.1%, P=0.133). However, the endoscope reached the terminal ileum in only 28 of 50 patients (6 in the PSC group and 22 in the non-PSC group). Furthermore, compared with patients in the non-PSC group, those in the PSC group presented more severe liver-associated symptoms and imaging findings. Patients in the PSC group had higher risks of jaundice (50.0% and 2.6%, respectively; P<0.001), liver cirrhosis (41.7% and 2.6%, respectively; P<0.001), hepatic decompensation (25.0% and 2.6%, respectively; P=0.013), and requiring LT (25.0% and 0%, respectively; P=0.001) than did patients in the non-PSC group. Among the 3 patients who received LT for the PSC, 1 patient passed away 7 years after LT due to septic shock. All of them, their UC disease activity were stable during the follow-up period. With regarding to treatment, all patients with UC and PSC received ursodeoxycholic acid (100% vs. 0%, P<0.001), whereas those without PSC did not. Otherwise, the frequency of administering 5-aminosalicylic acid (83.3% vs. 100%, P=0.054), steroids (58.3% vs. 52.6%, P=0.730), thiopurine (41.7% vs. 47.4%, P=0.730), and anti-tumor necrosis factor-α (0% vs. 21.0%, P=0.083) did not significantly differ between the groups. Patients with UC and PSC did not have a significantly higher risk of cancer (8.3% vs. 7.9%, P=0.679) or higher mortality (16.7% vs. 7.9%, P=0.377) than did patients with UC but without PSC. In the PSC-UC group, 1 patient developed colon cancer and 2 patients died (1 patient owing to hepatic failure and the other owing to colon cancer). In the non-PSC-UC group, 2 patients developed colon cancer and 1 patient developed acute myeloid leukemia. Three patients died (1 owing to HCV-related hepatic failure, 1 owing to colon cancer, and 1 owing to pneumonia), all of whom were aged over 60 years. The mortality rate did not significantly differ between the pediatric and adult groups (8.6% vs. 13.3%, P=0.629).

3. Comparison of Laboratory Characteristics between Patients with and without PSC

Compared with patients with UC but without PSC, those with UC and PSC had higher levels of serum total bilirubin (0.54 and 1.26 mg/dL, respectively; P=0.001), alanine aminotrans-ferase (12 and 73 U/L, respectively; P<0.001), alkaline phosphatase (75.5 and 275.5 U/L, respectively; P<0.001), γ-glutamyl transpeptidase (24.5 and 165 U/L, respectively; P=0.005), and prothrombin time (10.9 and 11.4 seconds, respectively; P=0.042). Furthermore, the hemoglobin level was significantly lower in the PSC-UC group than in the non-PSC-UC group (10.6 and 12.4 g/dL, respectively; P=0.002). The relevant data are listed in Table 4.

DISCUSSION

In this hospital-based cohort study, 1.57% prevalence of PSC was observed among Taiwanese patients with IBD; the prevalence was 3.1% in patients with UC and 0% in those with CD. Thus, all these IBD patients were diagnosed with UC. This finding is compatible with that of our previously published nationwide population-based study that showed a 1.6% prevalence of cholangitis in Taiwanese patients with IBD [13]. The prevalence of PSC in Indian patients with UC and CD was 0.4% and 0%, respectively [14], and that in Korean patients was 0.3% and 0.2%, respectively [5]. Meanwhile, 2.4% to 7.5% of patients with UC were diagnosed with PSC in Western countries [4]. The lower prevalence of PSC along with IBD in Asian countries than in Western countries may be attributed to underdiagnosis; alternatively, the prevalence could have actually been low. To the best of our knowledge, PSC was more common among patients with IBD in Taiwan than in other Asian countries.

We observed that patients with IBD and PSC were much younger than those with IBD but without PSC; in addition, men were more likely to develop PSC, especially in the pediatric group. Male predominance of PSC in children and adolescents was previously reported [15]. According to Vavricka et al. [6], 25% of patients with IBD and PSC developed PSC before the diagnosis of IBD, which indicates that in the majority of cases, PSC would be diagnosed after the diagnosis of IBD. Our results also demonstrated that in 25% of patients, PSC was diagnosed before IBD, in 33% of patients, PSC and IBD were simultaneously diagnosed, and in 42% of patients, PSC was diagnosed after IBD. Interestingly, in the majority of pediatric patients (60%), PSC and UC were simultaneously diagnosed. Our study also revealed that patients with UC and PSC had a higher risk of liver decompensation and increased requirement for LT. Therefore, routine survey and regular follow-up of liver and biliary profile function are recommended in pediatric male patients with IBD for early diagnosis and accurate management of PSC.

Our data demonstrated that underlying systemic disease or the extent or severity of colitis did not significantly differ between the PSC-UC and non-PSC-UC groups. Compared with patients with IBD alone, those with IBD and PSC have been reported to show predominant extensive colitis [16,17]. Even in the current study, patients with IBD and PSC presented with more extensive colitis (75%). Approximately 57.9% of patients in our matched control group presented with extensive colitis, whereas another hospital-based study conducted in Taiwan demonstrated that left-sided colitis was the predominant disease (42.7%), followed by extensive colitis (39.1%), in patients with UC [18]. There was no difference in the area of colitis between the 2 patient groups in this study, which may be attributed to the fact that our control group patients had more extensive colitis, as our hospital was a referral center for this condition. More rectal-sparing type (RST) UC was identified in our PSC group than in the non-PSC group (25% and 0%, respectively; P=0.001). In the study conducted by Park et al. [19], RST was detected in 3.3% of Korean patients with UC. RST was a relative disease status and could develop during disease progression [20]. Currently, it is well established that RST UC is associated with PSC [21]. Backwash ileitis was also reported as a distinct phenotype of patients with IBD and PSC [22]. In our study, although the proportion of ileitis seems higher in the group of patients with PSC, there was no statistical difference between the groups as terminal ileum intubation was achieved only in 28 patients (56%). Complete ileocolonoscopy was recommended for all patients with an initial diagnosis of IBD.

Compared with patients with UC but without PSC, those with PSC had higher levels of bilirubin, liver enzymes, biliary enzymes, and prothrombin time and a lower level of hemoglobin. The majority of these laboratory profiles were associated with liver reserve and could be prognostic factors for hepatic failure. Thus, it is reasonable that these patients with PSC had higher risks of liver cirrhosis and hepatic failure and were more likely to require LT.

In the PSC-UC group, 1 patient developed colon cancer, whereas in the non-PSC-UC group, 2 patients developed colon cancer. UC was associated with a 2- to 4-fold increased risk of CRC [23]. Compared with patients with IBD alone, those with IBD and PSC had an increased risk of CRC (odds ratio, 3.41; 95% confidence interval, 2.13–5.48) [24]. The low rate of cancer in the PSC-UC group might be attributed to the small number of patients in this group. We recommend annual surveillance colonoscopy for patients with IBD and PSC according to guidelines [25].

This study has some limitations. First, this was a retrospective study. Although we speculated that data regarding comprehensive laboratory studies would be available for hospitalized patients, not all patients had complete laboratory profiles or underwent cholangiography; hence, the prevalence of PSC might have been underestimated. Second, owing to the limited number of pediatric patients with IBD, the ratio of the PSC group to the control group was 1:2. The small patient number also led to a nonsignificant statistical result. Despite these limitations, the findings of this study help understand the characteristics of PSC concomitant with IBD in patients from Asian countries.

In conclusion, 1.57% prevalence of PSC was observed in Taiwanese patients with IBD, which was the highest in Asia. Pediatric male patients with UC had a higher risk of PSC. In the majority of patients, PSC was diagnosed along with or after IBD. Compared with patients with UC but without PSC, those with UC and PSC had higher levels of liver and biliary enzymes and higher risks of liver cirrhosis and hepatic failure. Routine survey and regular follow-up of hepatic and biliary profile function are recommended in pediatric male patients with IBD for early diagnosis and proper management of PSC to improve the outcomes of these patients.

NOTES

Funding Source

This work was supported by the National Taiwan University Hospital (NTUH 107-A139 to Wei SC) and the Liver Disease Prevention and Treatment Research Foundation, Taiwan (to Wei SC and Weng MT).

Conflict of Interest

Wong JM and Wei SC are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Author Contribution

Drafting of the manuscript: Weng MT, Wei SC. Analysis and interpretation of the data: Weng MT, Shih IL, Wong JM. Acquisition of the data: Shih IL, Tung CC, Leong YL. Statistical analysis: Weng MT. Critical revision of the manuscript for important intellectual content and study supervision: Shieh MJ, Wang CY, Wong JM. Study concept and design: Wei SC, Ni YH. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Fig. 1. Images of a 24-year-old man with ulcerative colitis and primary sclerosing cholangitis. (A) Axial T2-weighted magnetic resonance imaging with fat suppression shows dilated bilateral intrahepatic bile ducts (arrows) with stenosis at hepatic hilum. (B) Coronal thick slab magnetic resonance cholangiopancreatography shows dilated bilateral intrahepatic bile ducts (arrows) with stenosis at hepatic hilum. There is also a segmental narrowing of the common bile duct (arrowhead).

ir-2021-00042-suppl.pdf

Table 1.

Basic Characteristics of Patients with UC and PSC and Those with UC but without PSC

Characteristics	PSC UC	Non-PSC UC	P-value
Age (yr)	22.5 (12–27)	49.0 (32–59)	0.001^a
Male sex	10/12 (83.3)	217/371 (58.5)	0.085
Age ≤ 16 yr	5/5 (100)	13/34 (38.2)	0.015^a
Age > 16 yr	5/7 (71.4)	204/337 (60.5)	0.560

Values are presented as median (interquartile) or number/number (%).

^a Statistically significant, P<0.05. Fisher exact test was used for small samples, and Student t-test was used for quantitative variables. Chi-square test was used for categorical variables.

PSC, primary sclerosing cholangitis; UC, ulcerative colitis.

Table 2.

Basic Characteristics of 12 Patients with IBD (UC) and PSC

Patient No.	Age (yr)	Sex	PSC type	Time sequence of IBD and PSC diagnosis
1	3	M	IHBD+EHBD	At the same time
2	5	M	IHBD+EHBD	IBD after PSC
3	5	M	IHBD+EHBD	At the same time
4	12	M	IHBD	IBD before PSC
5	15	M	IHBD	At the same time
6	21	F	IHBD	IBD after PSC
7	24	M	IHBD+EHBD	IBD before PSC
8	25	M	IHBD+EHBD	IBD after PSC
9	27	M	IHBD+EHBD	IBD before PSC
10	42	F	IHBD+EHBD	At the same time
11	62	M	IHBD+EHBD	IBD before PSC
12	71	M	IHBD+EHBD	IBD before PSC

IBD, inflammatory bowel disease; UC, ulcerative colitis; PSC, primary sclerosing cholangitis; M, male; F, female; IHBD, intrahepatic bile duct; EHBD, extrahepatic bile duct.

Table 3.

Comparison of Clinical Characteristics between Patients with UC and PSC and Matched Patients with UC but without PSC

Variable	PSC UC (n = 12)	Non-PSC UC (n = 38)	P-value
Underlying diseases
Hypertension	1 (8.3)	2 (5.3)	0.696
Diabetes mellitus	0	2 (5.3)	0.417
Hyperlipidemia	0	1 (2.6)	0.570
Coronary artery disease	0	2 (5.3)	0.417
Chronic kidney disease	1 (8.3)	2 (5.3)	0.696
HBV carrier	0	0	-
HCV carrier	0	2 (5.3)	0.404
Colitis location/extent			0.271
Proctitis	2 (16.7)	4 (10.5)
Left side colon	1 (8.3)	12 (31.6)
Extensive	9 (75.0)	22 (57.9)
Rectal sparing	3 (25.0)	0	0.001^a
Backwash ileitis	2/6 (33.3)	2/22 (9.1)	0.133
Disease severity			0.513
Mild	6 (50.0)	15 (39.5)
Moderate	2 (16.7)	13 (34.2)
Severe	4 (33.3)	10 (26.3)
Liver involvement
Jaundice	6 (50.0)	1 (2.6)	< 0.001^a
Liver cirrhosis	5 (41.7)	1 (2.6)	0.001^a
Hepatic decompensation	3 (25.0)	1 (2.6)	0.013^a
Transplantation	3 (25.0)	0	0.001^a
Treatment
UDCA	12 (100)	0	0.001^a
5-ASA	10 (83.3)	38 (100)	0.054
Steroid	7 (58.3)	20 (52.6)	0.730
Thiopurine	5 (41.7)	18 (47.4)	0.730
Anti-TNF-α	0	8 (21.1)	0.083
Cancer	1 (8.3)	3 (7.9)	0.679
Mortality	2 (16.7)	3 (7.9)	0.377

Values are presented as number (%) or number/number (%).

^a Statistically significant, P<0.05. Chi-square test was used for categorical variables.

UC, ulcerative colitis; PSC, primary sclerosing cholangitis; HBV, hepatitis B virus; HCV, hepatitis C virus; UDCA, ursodeoxycholic acid; 5-ASA, 5-aminosalicylic acid, TNF, tumor necrosis factor.

Table 4.

Comparison of Laboratory Data between Patients with UC and PSC and Matched Patients with UC but without PSC

Parameter	PSC UC (n = 12)	Non-PSC UC (n = 38)	P-value
WBC (× 10³/μL)	6,145 ± 2,698	6,800 ± 3,493	0.956
Hb (g/dL)	10.60 ± 1.92	12.40 ± 2.15	0.002^a
T-Bil (mg/dL)	1.26 ± 3.40	0.54 ± 0.52	0.001^a
ALT (U/L)	73.00 ± 172.40	12.00 ± 16.59	< 0.001^a
ALP (U/L)	275.50 ± 231.50	75.50 ± 99.00	< 0.001^a
γ-GT (U/L)	165.00 ± 111.70	24.50 ± 108.10	0.005^a
PT (sec)	11.40 ± 5.36	10.90 ± 1.01	0.042^a
Alb (g/dL)	3.65 ± 0.53	4.25 ± 1.31	0.092
Cre (mg/dL)	0.60 ± 2.10	0.75 ± 0.44	0.246
CRP (mg/dL)	1.51 ± 1.92	0.29 ± 2.70	0.626

Value are presented as mean±standard deviation.

^a Statistically significant, P<0.05. Student t-test was used for quantitative variables.

UC, ulcerative colitis; PSC, primary sclerosing cholangitis; WBC, white blood cells; Hb, hemoglobin; T-Bil, total bilirubin; ALT, alanine aminotrans-ferase; ALP, alkaline phosphatase; γ-GT, gamma-glutamyl transpeptidase; PT, prothrombin time; Alb, albumin; Cre, creatinine; CRP, C-reactive protein.

REFERENCES

1. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181–1188.Article PubMed
2. Boonstra K, Weersma RK, van Erpecum KJ, et al. Populationbased epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045–2055.Article PubMed
3. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis: a comprehensive review. J Hepatol 2017;67:1298–1323.Article PubMed
4. de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015;21:1956–1971.Article PubMed PMC
5. Yang BR, Choi NK, Kim MS, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. PLoS One 2018;13:e0200363.Article PubMed PMC
6. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2015;21:1794–1800.Article PubMed
7. Folseraas T, Boberg KM. Cancer risk and surveillance in primary sclerosing cholangitis. Clin Liver Dis 2016;20:79–98.Article PubMed
8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;2:375–378.Article PubMed PMC
9. Núñez F P, Quera P R, Gomollón F. Primary sclerosing cholangitis and inflammatory bowel disease: intestine-liver interrelation. Gastroenterol Hepatol 2019;42:316–325.Article PubMed
10. Yen HH, Weng MT, Tung CC, et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest Res 2019;17:54–62.Article PubMed PMC
11. Wei SC, Shieh MJ, Chang MC, Chang YT, Wang CY, Wong JM. Long-term follow-up of ulcerative colitis in Taiwan. J Chin Med Assoc 2012;75:151–155.Article PubMed
12. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965–990.Article PubMed
13. Lin WC, Weng MT, Tung CC, et al. Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study. J Transl Med 2019;17:414.Article PubMed PMC
14. Singh B, Kedia S, Konijeti G, et al. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: frequency and relation with disease phenotype. Indian J Gastroenterol 2015;34:43–50.Article PubMed
15. Fagundes ED, Ferreira AR, Hosken CC, Queiroz TC. Primary sclerosing cholangitis in children and adolescents. Arq Gastroenterol 2017;54:286–291.Article PubMed
16. Fousekis FS, Theopistos VI, Mitselos IV, et al. Specific features of patients with inflammatory bowel disease and primary sclerosing cholangitis. J Clin Med Res 2019;11:81–88.Article PubMed PMC
17. Bajer L, Wohl P, Drastich P. PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis. Vnitr Lek 2018;64:659–664.Article PubMed
18. Chou JW, Lai HC, Chang CH, Cheng KS, Feng CL, Chen TW. Epidemiology and clinical outcomes of inflammatory bowel disease: a hospital-based study in central Taiwan. Gastroenterol Res Pract 2019;2019:4175923.Article PubMed PMC
19. Park SH, Yang SK, Park SK, et al. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. Can J Gastroenterol Hepatol 2014;28:125–130.Article PubMed PMC
20. Horio Y, Uchino M, Bando T, et al. Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies. BMC Surg 2017;17:59.Article PubMed PMC
21. Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep 2018;20:16.Article PubMed
22. Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver 2018;12:17–29.Article PubMed PMC
23. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639–645.Article PubMed
24. Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol 2016;28:383–390.Article PubMed
25. Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975–1984.PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Gut and Liver.2024; 18(2): 294. CrossRef
Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 276. CrossRef
Incidence and adverse clinical events of primary sclerosing cholangitis with ulcerative colitis
In Sub Han, Dong Hoon Baek, Seung Min Hong, Bong Eun Lee, Moon Won Lee, Gwang Ha Kim, Geun Am Song
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Experimental & Molecular Medicine.2023; 55(7): 1380. CrossRef
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef
Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
Kwang Woo Kim, Hyoun Woo Kang
Intestinal Research.2023; 21(4): 413. CrossRef
Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
Yong Eun Park
Intestinal Research.2022; 20(2): 157. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease

Intest Res. 2022;20(2):224-230. Published online February 8, 2022

DOI: https://doi.org/10.5217/ir.2021.00042

XML Download

Related articles

Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease

Characteristics	PSC UC	Non-PSC UC	P-value
Age (yr)	22.5 (12–27)	49.0 (32–59)	0.001^a
Male sex	10/12 (83.3)	217/371 (58.5)	0.085
Age ≤ 16 yr	5/5 (100)	13/34 (38.2)	0.015^a
Age > 16 yr	5/7 (71.4)	204/337 (60.5)	0.560

Patient No.	Age (yr)	Sex	PSC type	Time sequence of IBD and PSC diagnosis
1	3	M	IHBD+EHBD	At the same time
2	5	M	IHBD+EHBD	IBD after PSC
3	5	M	IHBD+EHBD	At the same time
4	12	M	IHBD	IBD before PSC
5	15	M	IHBD	At the same time
6	21	F	IHBD	IBD after PSC
7	24	M	IHBD+EHBD	IBD before PSC
8	25	M	IHBD+EHBD	IBD after PSC
9	27	M	IHBD+EHBD	IBD before PSC
10	42	F	IHBD+EHBD	At the same time
11	62	M	IHBD+EHBD	IBD before PSC
12	71	M	IHBD+EHBD	IBD before PSC

Variable	PSC UC (n = 12)	Non-PSC UC (n = 38)	P-value
Underlying diseases
Hypertension	1 (8.3)	2 (5.3)	0.696
Diabetes mellitus	0	2 (5.3)	0.417
Hyperlipidemia	0	1 (2.6)	0.570
Coronary artery disease	0	2 (5.3)	0.417
Chronic kidney disease	1 (8.3)	2 (5.3)	0.696
HBV carrier	0	0	-
HCV carrier	0	2 (5.3)	0.404
Colitis location/extent			0.271
Proctitis	2 (16.7)	4 (10.5)
Left side colon	1 (8.3)	12 (31.6)
Extensive	9 (75.0)	22 (57.9)
Rectal sparing	3 (25.0)	0	0.001^a
Backwash ileitis	2/6 (33.3)	2/22 (9.1)	0.133
Disease severity			0.513
Mild	6 (50.0)	15 (39.5)
Moderate	2 (16.7)	13 (34.2)
Severe	4 (33.3)	10 (26.3)
Liver involvement
Jaundice	6 (50.0)	1 (2.6)	< 0.001^a
Liver cirrhosis	5 (41.7)	1 (2.6)	0.001^a
Hepatic decompensation	3 (25.0)	1 (2.6)	0.013^a
Transplantation	3 (25.0)	0	0.001^a
Treatment
UDCA	12 (100)	0	0.001^a
5-ASA	10 (83.3)	38 (100)	0.054
Steroid	7 (58.3)	20 (52.6)	0.730
Thiopurine	5 (41.7)	18 (47.4)	0.730
Anti-TNF-α	0	8 (21.1)	0.083
Cancer	1 (8.3)	3 (7.9)	0.679
Mortality	2 (16.7)	3 (7.9)	0.377

Parameter	PSC UC (n = 12)	Non-PSC UC (n = 38)	P-value
WBC (× 10³/μL)	6,145 ± 2,698	6,800 ± 3,493	0.956
Hb (g/dL)	10.60 ± 1.92	12.40 ± 2.15	0.002^a
T-Bil (mg/dL)	1.26 ± 3.40	0.54 ± 0.52	0.001^a
ALT (U/L)	73.00 ± 172.40	12.00 ± 16.59	< 0.001^a
ALP (U/L)	275.50 ± 231.50	75.50 ± 99.00	< 0.001^a
γ-GT (U/L)	165.00 ± 111.70	24.50 ± 108.10	0.005^a
PT (sec)	11.40 ± 5.36	10.90 ± 1.01	0.042^a
Alb (g/dL)	3.65 ± 0.53	4.25 ± 1.31	0.092
Cre (mg/dL)	0.60 ± 2.10	0.75 ± 0.44	0.246
CRP (mg/dL)	1.51 ± 1.92	0.29 ± 2.70	0.626

Table 1. Basic Characteristics of Patients with UC and PSC and Those with UC but without PSC

Values are presented as median (interquartile) or number/number (%).

Statistically significant, P<0.05. Fisher exact test was used for small samples, and Student t-test was used for quantitative variables. Chi-square test was used for categorical variables.

PSC, primary sclerosing cholangitis; UC, ulcerative colitis.

Table 2. Basic Characteristics of 12 Patients with IBD (UC) and PSC

IBD, inflammatory bowel disease; UC, ulcerative colitis; PSC, primary sclerosing cholangitis; M, male; F, female; IHBD, intrahepatic bile duct; EHBD, extrahepatic bile duct.

Table 3. Comparison of Clinical Characteristics between Patients with UC and PSC and Matched Patients with UC but without PSC

Values are presented as number (%) or number/number (%).

Statistically significant, P<0.05. Chi-square test was used for categorical variables.

UC, ulcerative colitis; PSC, primary sclerosing cholangitis; HBV, hepatitis B virus; HCV, hepatitis C virus; UDCA, ursodeoxycholic acid; 5-ASA, 5-aminosalicylic acid, TNF, tumor necrosis factor.

Table 4. Comparison of Laboratory Data between Patients with UC and PSC and Matched Patients with UC but without PSC

Value are presented as mean±standard deviation.

Statistically significant, P<0.05. Student t-test was used for quantitative variables.